Document ID: chunk:federal_register_of_legislation:F2018L01183:reg:9:p3
Version: federal_register_of_legislation:F2018L01183
Segment Type: reg
Provision Reference: reg 9 (pt 3/3)
Character Range: 10340–11619

dose of the therapy was received within the one year before the clinical worsening of adrenal insufficiency;
Note: glucocorticoid therapy as specified is defined in the Schedule 1 - Dictionary.
(21)      being treated with medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection:
(a)          for a continuous period of at least four weeks before the clinical worsening of adrenal insufficiency; and
(b)          where such treatment has ceased, the last dose was received within the three months before the clinical worsening of adrenal insufficiency;
(22)      having hypopituitarism with adrenocorticotrophic hormone deficiency, at the time of the clinical worsening of adrenal insufficiency;
(23)      having a critical illness or injury within the one year before the clinical worsening of adrenal insufficiency;
Note: critical illness or injury is defined in the Schedule 1 - Dictionary.
(24)      for adrenal crisis only, having an acute, severe stressor within the seven days before the clinical worsening of adrenal insufficiency;
Note: acute, severe stressor and adrenal crisis are defined in the Schedule 1 - Dictionary.
(25)      inability to obtain appropriate clinical management for adrenal insufficiency.